$LYEL News
Last published 1w ago
- 1w agoLYELLyell Immunopharma, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoLYELLyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026GlobeNewswireAnnounced updated clinical data in more than 80 patients from the ongoing PiNACLE pivotal trial in patients with 3L+ R/R LBCL and from the Phase 1/2 trial 2L cohort of ronde-cel in abstracts accepted for presentation at
- 1w agoLYELLyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA SubmissionGlobeNewswireInvestors include ARCH Venture Partners, Adage Capital Management LP, Caligan Partners LP, RTW Investments, a leading mutual fund and other new and existing institutional investors.Ronde-cel, a next-generation CD19/CD20
- 1w agoLYELLyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell LymphomaGlobeNewswireRonde-cel achieved a 91% overall response rate and 77% complete response rate; median progression-free survival not reached and estimated 6-month duration of complete response of 92% in 44 patients with 3L+ R/R LBCL in
- 1w agoLYELLyell Immunopharma To Participate in November Investor EventsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell
- 1mo agoLYELBAIRD 2026 GLOBAL HEALTHCARE CONFERENCE - LYELL IMMUNOPHARMA INCEarnings Call TranscriptsGreat. Thank you all for taking the time to join us for another session at the Baird Healthcare Conference today. My name is Jack Allen, for those who I haven't met in the audience, and I cover the biotech space. And for
- 1mo agoLYELBAIRD 2026 GLOBAL HEALTHCARE CONFERENCE - LYELL IMMUNOPHARMA INCEarnings Call TranscriptsGreat. Thank you all for taking the time to join us for another session at the Baird Healthcare Conference today. My name is Jack Allen, for those who I haven't met in the audience, and I cover the biotech space. And for
- 1mo agoLYELLyell Immunopharma To Participate in the Baird 2026 Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell
- 2mo agoLYELLyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal CancerGlobeNewswireTechnology transfer to LyFE Manufacturing Center™ completed following FDA review of improved manufacturing process and updated analytical methodsDosing of additional patients with the new process at LyFE continues with
- 3mo agoLYELLyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026GlobeNewswirePiNACLE pivotal clinical trial evaluating ronde-cel in 3L+ patients with LBCL on track to report additional data in second half of 2026, with pivotal data expected mid-2027 and BLA submission expected to follow in the
- 4mo agoLYELLyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell
- 5mo agoLYELLyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 CongressGlobeNewswireMore than 100 patients treated with ronde-cel in 2L and 3L+ LBCL, with a manufacturing success rate of 97%No Grade ≥ 3 CRS and low rates of Grade ≥ 3 ICANS, supporting outpatient administrationTranslational data support
- 5mo agoLYELLyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 ExpansionGlobeNewswireGastrointestinal prophylaxis reduced Grade ≥ 2 diarrhea/colitis from 55% without prophylaxis to 10% with prophylaxisThe maximum tolerated dose has not yet been determinedNo difference is observed in GCC CAR T-cell
- 5mo agoLYELLyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 CongressGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell
- 5mo agoLYELLyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell
- 5mo agoLYEL2026 STIFEL VIRTUAL TARGETED ONCOLOGY FORUM - LYELL IMMUNOPHARMA INCEarnings Call TranscriptsAll right. Good afternoon, everyone. I'm Stephen Willey, one of the senior biotech analysts here at Stiefel. I'm very glad to have with us in the next session, Lynn Seeley, who is the president and CEO of Lyell. Lynn, th
- 6mo agoLYELLyell Immunopharma Announces Participation in May Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell
- 6mo agoLYELLyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026GlobeNewswirePiNACLE pivotal clinical trial evaluating ronde-cel in patients with LBCL in third- or later-line setting on track to report additional data in second half of 2026, with pivotal data expected mid-2027 and BLA submission
- 7mo agoLYEL25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE - LYELL IMMUNOPHARMA INCEarnings Call TranscriptsGood morning, everyone, and thank you for joining us at the second day of the Needham Health Care Conference. My name is Gil Bloom, and I'm a senior biotech analyst here at Needham & Company, and they cover the cell and
- 7mo agoLYELLyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell
- 8mo agoLYELLyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial ResultsGlobeNewswirePatient dosing has commenced in first-of-its-kind Phase 3 head-to-head CAR T-cell 2L randomized controlled clinical trial (PiNACLE-H2H) in patients with large B-cell lymphoma, and the 3L+ pivotal trial (PiNACLE)
- 8mo agoLYELPRQRLyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business OfficerGlobeNewswireClosing of additional $50 million tranche of $100 million equity private placement after achievement of clinical milestone for rondecabtagene autoleucelSmital Shah appointed Chief Financial and Business Officer SOUTH
- 8mo agoLYELLyell Immunopharma Announces Participation in March Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies
- 9mo agoLYELLyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell LymphomaGlobeNewswirePiNACLE – H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator's choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving
- 10mo agoCRBUGTBPLYELNRIX+1Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market SurgeGlobeNewswireVANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity Insider News Commentary – The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034[1], driven by a
- 10mo agoGTBPREGNGMABAUTL+1Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030PR NewswireUSA News Group News Commentary – The recent FDA approval in November of the first bispecific antibody combination for second-line blood cancer...
- 11mo agoLYELLyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and ExpositionGlobeNewswire93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting83% overall response and 61% complete response rates in
- 12mo agoLYELLyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025GlobeNewswireAcquired exclusive global rights to LYL273, a novel GCC-targeted CAR T-cell product candidate that has demonstrated a 67% overall response rate, an 83% disease control rate and a manageable safety profile at the highest
- 1y agoLYELLyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal CancerGlobeNewswireLYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer
- 1y agoLYELLyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and ExpositionGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with
- 1y agoLYELLyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering CommitteeGlobeNewswirePiNACLE - H2H will evaluate rondecabtagene autoleucel (ronde-cel) versus investigator's choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving treatment in the second
- 1y agoLYELLyell Immunopharma Announces Participation in September Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing next-generation CAR T-cell
- 1y agoLYELLyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025GlobeNewswirePresented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphomaInitiated the PiNACLE pivotal trial of
- 1y agoONCYCELCEVAXLYEL+1Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer TreatmentsPR NewswireEquity Insider News Commentary – The average age of cancer patients is getting younger, as experts are urgently examining the rise of early-onset...
- 1y agoLYELLyell Immunopharma Announces up to $100 Million Equity Private PlacementGlobeNewswireSOUTH SAN FRANCISCO, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, today announced
- 1y agoLYELLyell Immunopharma to Participate in the H.C. Wainwright "HCW@Home" SeriesGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, announced today
- 1y agoLYELLyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell LymphomaGlobeNewswireLYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25)71% of patients with complete response
- 1y agoLYELLyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive AppointmentsGlobeNewswireMark J. Bachleda, PharmD, MBA appointed as independent member of the Board of DirectorsDavid Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corporate Secretary, and Jarrad Aguirre,
- 1y agoLYELLyell Immunopharma to Participate in the Goldman Sachs Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer,
- 1y agoLYELLyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025GlobeNewswirePresenting new clinical data from Phase 1/2 multi-center clinical trial of LYL314, a next-generation dual‑targeting CD19/CD20 CAR T-cell product candidate for the treatment of relapsed and/or refractory large B‑cell
- 1y agoLYELLyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025GlobeNewswireSOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer,
- 1y agoLYELLyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell LymphomaGlobeNewswireRMAT designation was granted based on promising clinical data from the ongoing Phase 1/2 trial of LYL314 in patients with relapsed and/or refractory large B-cell lymphoma.RMAT designation recognizes the potential of
- 1y agoLYELLyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024GlobeNewswireAcquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate for the treatment of aggressive large B-cell lymphoma
- 1y agoLYELLyell Immunopharma Announces Participation in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer,
- 1y agoLYELLyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare ConferenceGlobeNewswireAccelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025 and expect to initiate a pivotal trial in the 2nd line by early 2026Presenting additional data
- 1y agoLYELLyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual MeetingGlobeNewswireObjective response rate (ORR) of 94% and a complete response (CR) rate of 71% demonstrated after IMPT-314 treatment in CAR T-naïve patients with large B-cell lymphoma who had received at least 2 prior lines of
- 2y agoLYELLyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024GlobeNewswireAcquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate with strong Phase 1 clinical data in patients with aggressive
- 2y agoLYELLyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual MeetingGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid
- 2y agoLYELLyell Immunopharma Completes Acquisition of ImmPACT BioGlobeNewswireAcquisition strengthens Lyell's clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate expected to initiate pivotal development in 2025 in patients in the 3rd line
- 2y agoLYELLyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell TherapiesGlobeNewswireStrengthens Lyell's clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidateData from ImmPACT's multi-center Phase 1-2 clinical trial of IMPT-314 in patients with large